Several other institutional investors also recently added to or reduced their stakes in the stock. Cribstone Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at approximately $123,000. Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Finally, Financial Architects Inc increased its position in Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 56.27% of the company’s stock.

Naples Global Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,881 shares of the company’s stock after buying an additional 2,275 shares during the period. Naples Global Advisors LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $793,000 as of its most recent SEC filing.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 1.61% on Tuesday, hitting $18.29. The stock had a trading volume of 51,308,881 shares. Teva Pharmaceutical Industries Limited has a 1-year low of $18.21 and a 1-year high of $55.45. The stock has a market capitalization of $18.58 billion, a price-to-earnings ratio of 234.49 and a beta of 0.46. The company has a 50-day moving average price of $32.05 and a 200-day moving average price of $32.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.25 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th will be given a $0.085 dividend. The ex-dividend date is Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 1.86%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -18.95%.

A number of equities research analysts have recently issued reports on the stock. Credit Suisse Group set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 target price for the company in a research report on Monday, July 24th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BidaskClub cut shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, twenty-one have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and a consensus target price of $39.19.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.